MiraOmics
MiraOmics is a boutique Berkeley-based bioinformatics firm providing multi-omics integration, spatial transcriptomics, and cell type annotation services to early-stage biotech companies, pharma/biotech CROs, and investors. Its core proprietary platform, MiraTyper, delivers universal cross-platform cell classification using generative AI embeddings and transformer architecture.
- Company typePrivate
- Founded2014
- HeadquartersBerkeley, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What MiraOmics does
MiraOmics is a boutique bioinformatics firm founded by Eugene Bolotin and based in Berkeley, California, providing computational biology services to the cell therapy and large molecule development segments of the biopharma industry. The company combines multi-omics integration, spatial transcriptomics, and cell type annotation to serve early-stage biotech companies building investor-ready data packages, pharma and biotech CROs seeking technology benchmarking and new service lines, biologists, bioinformaticians, and investors conducting computational biology due diligence. Engagements range from per-hour video/phone consultations (with startup discounts) to full analytics contracts spanning design of experiments through IND-ready report generation, plus long-term strategy and fractional advisory engagements.
The company's core technical asset is MiraTyper, a proprietary universal cell classification platform trained on a 100M+ cell CellXGene corpus using hybrid generative AI embeddings and transformer-based classification. MiraTyper classifies 377 cell types across tissues, species, and platforms (10x Genomics, CosMx, Visium) without requiring tissue-specific model selection, and includes zero-shot learning, confidence scores, and pre-harmonized Cell Ontology labels. Disclosed performance includes hierarchical F1 scores of 0.84–0.99, processing of approximately 110 million cells in 30 minutes, and a corrected h-F1 of 0.813 on a 708,983-cell Xenium lymph node dataset. The firm complements this with adjacent service lines: target discovery and validation pipelines, clinical and translational biomarker pipelines (including CAR-T frameworks referenced in FDA submissions), manufacturing analytics for cell therapy, spatial transcriptomics with H&E integration, and bioinformatics due diligence for investors.
MiraOmics operates a sales-led professional services GTM with free 30-minute consultations as the lead qualification step, supported by content marketing (blog, case studies, LinkedIn) and affiliate listings on Science Exchange and Scientist.com. The company has 1–10 disclosed employees, is founder-led with no disclosed external funding, and maintains a CISO (Serge Bery) to support pharma-grade security positioning required by enterprise clients. Note: source materials report a founding year of 2014 (company history), while firmographics data lists 2024 — this discrepancy is flagged but unresolved in the available data.
MiraOmics firmographics
Firmographics- Name
- MiraOmics
- Legal name
- Miraomics
- Website
- https://miraomics.bio
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MiraOmics is a boutique Berkeley-based bioinformatics firm providing multi-omics integration, spatial transcriptomics, and cell type annotation services to early-stage biotech companies, pharma/biotech CROs, and investors. Its core proprietary platform, MiraTyper, delivers universal cross-platform cell classification using generative AI embeddings and transformer architecture.
- Ownership category
- akta.pro rank
MiraOmics industry classification
Industry- Product category
- Bioinformatics Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690), Other Scientific and Technical Consulting Services (54169), All Other Professional, Scientific, and Technical Services (54199)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industries
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Proteomics & Mass Spectrometry Services (HLAGANAB), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where MiraOmics is headquartered
LocationHeadquarters
- HQ city
- Berkeley
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MiraOmics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Professional Services - Consulting: Analytics consulting and bioinformatics services including video/phone consultations on specific projects (per/hour basis with discounts for startups), and long-term strategy engagements with in-person visits.
- Analytics Contracts: Full data handling from design of experiments through data transfer to report generation. State-of-the-art pharma-grade security. Pricing dependent on scope.
- Bioinformatics Due Diligence: Technology evaluation and review services for investors considering biotech investments with complicated drug discovery analytics platforms.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | One time | Free initial consultation |
| Other | Pay-as-you-go | Video/Phone consultation - short term |
| Other | Multi-year contract | Analytics contract - full project engagement |
| Other | Multi-year contract | Strategy engagement - long term |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
MiraOmics product offering
Product offeringCore offering
MiraOmics is a boutique bioinformatics shop that delivers expert analytics, scientific consulting, and advisory services centered on cell therapy and large molecule development. Core offerings include multi-omics integration, spatial transcriptomics pipelines, clinical and translational biomarker pipelines, manufacturing analytics for cell therapy, and proprietary MiraTyper universal cell classification technology, supported by IND/FDA submission experience.
Product overview
MiraOmics is a boutique bioinformatics company offering a portfolio of computational biology solutions centered around MiraTyper, their universal cell classification platform. MiraTyper provides batch-resistant, pan-organ cell type classification across 377+ cell types using hybrid generative AI embeddings and transformer-based classification. The company complements this core product with professional services including target discovery and validation through multiomics integration, clinical and translational biomarker pipelines (including CAR-T frameworks for FDA submissions), manufacturing analytics pipelines for cell therapy, spatial transcriptomics integration, and bioinformatics due diligence and scientific advisory services.
Differentiator
Problem solved
Functional benefit
Brands
- MiraTyper: A universal cell-type classification platform developed by Miraomics that delivers fast, accurate, and reproducible cell classification across hundreds of cell types, multiple data modalities, and diverse tissues without tissue-specific model selection. It uses hybrid generative AI embeddings with transformer-based classification.
Products and services
- MiraTyper Universal cell classification platform delivering fast, accurate, and reproducible cell type annotation across hundreds of cell types, multiple data modalities, and diverse tissues without tissue-specific model selection, using hybrid generative AI embeddings and transformer-based classification trained on 100M+ cells. Built for biotech, pharma, and cell therapy use cases including single-cell and spatial transcriptomics.
- Target Discovery and Validation Services Multiomics-based target identification combining single-cell, spatial, proteomics, and bulk datasets into integrated pipelines that estimate and segment target populations, identify causal genes and pathways, and deliver IND-ready data packages for cell therapy and large molecule development. Targeted at biotech and pharma R&D teams.
- Clinical and Translational Biomarker Pipelines Integrated single-cell, spatial, bulk, and proteomic pipelines that surface predictive biomarkers, PD signatures, and tumor microenvironment stratification, including CAR-T biomarker frameworks used in FDA submissions. Targeted at translational and clinical biomarker teams in biotech and pharma.
- Manufacturing Analytics Pipelines for Cell Therapy Automated, reproducible pipelines for cell-composition analysis, in-process control analytics, release-criteria development, and multimodal QC data integration supporting clinical manufacturing consistency and regulatory requirements. Targeted at cell therapy manufacturing and QC teams.
- Spatial Transcriptomics + H&E Integration Pipelines combining spatial data, histology, and imaging features with downstream single-cell integration enabling biodistribution analysis, tissue-engineering validation, immune infiltration profiling, and mechanism-of-action discovery. Targeted at translational research and tissue biomarker teams.
- Single-Cell and Multimodal Integration Pipelines Unified pipelines for scRNA-seq, ATAC-seq, TCR/BCR, proteomics, and spatial datasets across donors and timepoints to model cell states, clonotypes, and therapeutic responses. Targeted at biotech and pharma discovery and translational teams.
- Bioinformatics Due Diligence Technology evaluation and second-opinion services for investors reviewing NGS or multi-omics based drug identification pipelines, or evaluating candidates for computational biology positions. Targeted at biotech investors and acquirers.
- Scientific Advisory Strategy consulting for analytics teams from startups to big pharma, covering business analytics strategy, CRO vs in-house decisions, FTE planning, cloud vs on-premises infrastructure, and buy vs build decisions. Targeted at analytics leadership and executive teams at biotech and pharma companies.
Quantifiable outcome
- MiraTyper achieves 96.2% exact-match accuracy at confidence >= 0.5 on pancreatic T2D datasets (77.8% coverage)
- +4 more outcomes
Companies that use MiraOmics
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
MiraOmics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
MiraOmics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor.
- Science ExchangeminorService provider/vendor listed in 'Our affiliates' section. Science Exchange is a scientific services marketplace platform.
- Scientist.comminorService provider/vendor listed in 'Our affiliates' section. Scientist.com is a marketplace for scientific research services.
- LatchminorService provider/vendor listed in 'Our affiliates' section. Latch provides software solutions for building access.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
MiraOmics competitors and assessment
Company assessmentDirect peers
- Partek: Provides bioinformatics software and services for single-cell and bulk genomics analyses, including cell-type classification and spatial transcriptomics. Directly comparable to MiraOmics on multi-omics analytics and consulting for pharma/biotech customers.
- DNAnexus: Cloud-based bioinformatics platform for genomics and multi-omics data analysis used by pharma and clinical customers. Comparable technology stack and customer segment to MiraOmics' analytics contracts.
- Velsera (formerly Seven Bridges Genomics): Genomics and multi-omics data analysis platform with clinical-grade pipelines and pharma services. Directly comparable on multi-omics interpretation and pharma/CRO customer base.
- Genedata: Enterprise bioinformatics platform serving biopharma R&D with multi-omics data analysis, biomarker discovery, and cell therapy analytics. Comparable to MiraOmics' pharma-facing, IND-grade analytics positioning.
- Qlucore: Bioinformatics tools and services for omics data visualization and analysis, including single-cell workflows. Overlaps with MiraOmics on cell-type annotation and multi-omics consulting for biotech clients.
Broad incumbents
- Illumina: Sequencing and multi-omics platform giant with bioinformatics offerings (e.g., DRAGEN, BaseSpace). Relevant incumbent given founder lineage and the company's genomics analytics focus.
- Dotmatics: Scientific R&D informatics platform used across pharma for biology, chemistry, and lab data. Broad incumbent with adjacent analytics offerings to MiraOmics' scientific consulting practice.
- 10x Genomics: Dominant spatial transcriptomics and single-cell platform (Visium, Xenium, Chromium) whose datasets MiraTyper is benchmarked against. A broader incumbent that overlaps with MiraOmics on cell-type annotation use cases and serves many of the same biotech/pharma customers.
Emerging players
- Emedgene: AI-driven genomics interpretation platform focused on clinical and research variant/multi-omics data. Tangentially comparable as a smaller, AI-native bioinformatics player serving pharma/biotech.
- Novogene: Genomics CRO providing sequencing and bioinformatics services including single-cell and multi-omics. Comparable service-led model for biotech/pharma, though with a much broader wet-lab footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MiraOmics social profiles
Digital presenceMiraOmics financial estimates
Financial estimateRevenue estimate
Valuation estimate
MiraOmics leadership team
Management profileNumber of profiles
Profiles3 records
MiraOmics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MiraOmics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MiraOmics
What does MiraOmics do?
MiraOmics is a boutique bioinformatics shop that delivers expert analytics, scientific consulting, and advisory services centered on cell therapy and large molecule development. Core offerings include multi-omics integration, spatial transcriptomics pipelines, clinical and translational biomarker pipelines, manufacturing analytics for cell therapy, and proprietary MiraTyper universal cell classification technology, supported by IND/FDA submission experience.
Is MiraOmics a public or private company?
MiraOmics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MiraOmics founded?
MiraOmics was founded in 2014. It employs 1 to 10 people.
Where is MiraOmics based?
MiraOmics is headquartered in Berkeley, United States, in the North America region.
How does MiraOmics make money?
Three revenue lines are on record. Professional Services - Consulting is the primary driver. The others are analytics Contracts and bioinformatics Due Diligence.
Who are MiraOmics's main competitors?
Direct peers on record are Partek, DNAnexus, Velsera (formerly Seven Bridges Genomics), Genedata and Qlucore. Broad incumbents are Illumina, Dotmatics and 10x Genomics. Emerging players are Emedgene and Novogene.
Does MiraOmics have an API?
No public API is recorded for MiraOmics.
What industry is MiraOmics in?
MiraOmics's product category is Bioinformatics Services. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714.